N
Naveenchandra Suryadevara
Researcher at Vanderbilt University Medical Center
Publications - 46
Citations - 4882
Naveenchandra Suryadevara is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Monoclonal antibody & Epitope. The author has an hindex of 18, co-authored 40 publications receiving 2431 citations. Previous affiliations of Naveenchandra Suryadevara include United States Department of Veterans Affairs & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Seth J. Zost,Pavlo Gilchuk,James Brett Case,Elad Binshtein,Rita E. Chen,Joseph P. Nkolola,Alexandra Schäfer,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,David R. Martinez,Lauren E. Williamson,Elaine C. Chen,Taylor Jones,Samuel Day,Luke Myers,Ahmed O. Hassan,Natasha M. Kafai,Emma S. Winkler,Julie M. Fox,Swathi Shrihari,Benjamin K. Mueller,Jens Meiler,Jens Meiler,Abishek Chandrashekar,Noe B. Mercado,James J. Steinhardt,Kuishu Ren,Yueh-Ming Loo,Nicole L. Kallewaard,Broc T. McCune,Shamus P. Keeler,Michael J. Holtzman,Dan H. Barouch,Lisa E. Gralinski,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +41 more
TL;DR: An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
Journal ArticleDOI
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.
Allison J. Greaney,Allison J. Greaney,Tyler N. Starr,Pavlo Gilchuk,Seth J. Zost,Elad Binshtein,Andrea N. Loes,Andrea N. Loes,Sarah K Hilton,John Huddleston,Rachel Eguia,Katharine H.D. Crawford,Katharine H.D. Crawford,Adam S. Dingens,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,Paul W. Rothlauf,Paul W. Rothlauf,Zhuoming Liu,Sean P. J. Whelan,Robert H. Carnahan,Robert H. Carnahan,James E. Crowe,James E. Crowe,Jesse D. Bloom,Jesse D. Bloom,Jesse D. Bloom +27 more
TL;DR: A deep mutational scanning method is described to map how all amino-acid mutations in the RBD affect antibody binding, and this method is applied to 10 human monoclonal antibodies to enable rational design of antibody therapeutics and assessment of the antigenic consequences of viral evolution.
Journal ArticleDOI
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
Rita E. Chen,Xianwen Zhang,James Brett Case,Emma S. Winkler,Yang Liu,Laura A. VanBlargan,Jianying Liu,John M. Errico,Xuping Xie,Naveenchandra Suryadevara,Pavlo Gilchuk,Seth J. Zost,Stephen Tahan,Lindsay Droit,Jackson S. Turner,Wooseob Kim,Aaron J. Schmitz,Mahima Thapa,David Wang,Adrianus C. M. Boon,Rachel M. Presti,Jane A. O’Halloran,Alfred H.J. Kim,Parakkal Deepak,Dora Pinto,Daved H. Fremont,James E. Crowe,Davide Corti,Herbert W. Virgin,Herbert W. Virgin,Ali H. Ellebedy,Pei Yong Shi,Michael S. Diamond +32 more
TL;DR: In this article, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, the authors report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants.
Journal ArticleDOI
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19.
Matthew C. Woodruff,Richard P. Ramonell,Doan C. Nguyen,Kevin S. Cashman,Ankur Singh Saini,Natalie S. Haddad,Ariel Ley,Shuya Kyu,J. Christina Howell,Tugba Ozturk,Saeyun Lee,Naveenchandra Suryadevara,James Brett Case,Regina Bugrovsky,Weirong Chen,Jacob Estrada,Andrea Morrison-Porter,Andrew Derrico,Fabliha Anam,Monika Sharma,Henry M. Wu,Sang N. Le,Scott A. Jenks,Christopher M. Tipton,Bashar S. Staitieh,John L. Daiss,Eliver Ghosn,Michael S. Diamond,Robert H. Carnahan,James E. Crowe,William T. Hu,F. Eun-Hyung Lee,Ignacio Sanz +32 more
TL;DR: Overall, these findings strongly suggest a pathogenic role for immune activation in subsets of patients with COVID-19, and provide further evidence that targeted immunomodulatory therapy may be beneficial in specific patient subpopulations and can be informed by careful immune profiling.
Journal ArticleDOI
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Seth J. Zost,Pavlo Gilchuk,Rita E. Chen,James Brett Case,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,Elaine C. Chen,Elad Binshtein,Swathi Shrihari,Mario A. Ostrowski,Helen Y. Chu,Jonathan E. Didier,Keith W. MacRenaris,Taylor Jones,Samuel Day,Luke Myers,F. Eun-Hyung Lee,Doan C. Nguyen,Ignacio Sanz,David R. Martinez,Paul W. Rothlauf,Paul W. Rothlauf,Louis Marie Bloyet,Sean P. J. Whelan,Sean P. J. Whelan,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +32 more
TL;DR: A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19, and demonstrates the speed and robustness of advanced antibody discovery platforms.